Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTAM: Effect of UGT inhibition with probenecid on endoxifen exposure in tamoxifen-treated breast cancer patients
2019-004854-27Phase 4Completed
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of probenecid in breast cancer (2 arms), sponsored by Erasmus MC Cancer Institute. Primary endpoint: Endoxifen AUC. Started Jan 2020; status: completed.
02
Drugs
probenecid
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-004854-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004854-27.